ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

GlaxoSmithKline: Complied With Indian Rules In Getting Heart, Lung Drug Approved

BANGALORE -(Dow Jones)- GlaxoSmithKline PLC (GSK) said Thursday the company was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs to treat a "rare disease which is life threatening and debilitating." The multinational drug maker's comments come in response to an Indian parliamentary panel report that said the heart and lung drug was among the medicines that were approved for sale by the country's drug regulator without mandatory final-stage clinical trials being conducted. The report, tabled in parliament Tuesday, pulled up the Central Drugs Standard Control Organization for irregularities in approving certain drugs as it had failed to obtain scientific evidence to establish their effectiveness and safety profile in treating Indian patients. It also alleged collusion among drug makers, experts like private and government doctors and CDSCO officials in the granting of approvals to certain drugs in the country. In addition to GlaxoSmithKline's ambrisentan, the report named some drugs made by Novartis AG (NOVN.VX), Eli Lilly & Co. (LLY) and India's Cipla Ltd. (500087.BY) as being approved for sale in India without trials. Ambrisentan was approved in Europe in 2008 and in the U.S. in 2007 and is currently available in 43 countries worldwide, a GlaxoSmithKline spokesman said in a statement. The company added that it had submitted the complete global clinical data set to regulatory authorities in India in 2009 and that ambrisentan gained marketing approval in the country in 2010. -By Rumman Ahmed, Dow Jones Newswires; 91-9845104173;

Stock News for Novartis (NVS)
10/12/201508:00:43Amgen's Prolia beats standard-of-care treatment in postmenopausal...
09/30/201519:04:00ADR Shares End Higher; JinkoSolar, Petrobras Trade Actively
09/30/201509:57:00United Therapeutics, Novartis Settle Dispute Over Generic Remodulin
09/25/201519:45:00Exelixis Reports Favorable Trial Results for Kidney Cancer Drug
09/23/201510:50:00Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive...
09/11/201516:21:00Novartis Heart Drug Overpriced, Group Says -- Update
09/11/201512:40:00Novartis Heart Drug Overpriced, Group Says
09/11/201512:26:00New Novartis Heart-Failure Drug Should Cost 17% Less, Research...
09/03/201513:11:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.--3rd...
09/03/201507:14:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S...
09/03/201505:24:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201504:00:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201502:49:00Novartis to Begin Selling Copy of Amgen's Neupogen in US
09/02/201516:30:00Novartis Closer to Selling Copy of Amgen's Neupogen
09/02/201516:22:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen...
09/02/201516:16:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen
09/02/201502:00:00Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs
09/01/201502:32:00Novartis Gets EU Approval For Skin Cancer Drugs Tafinlar, Mekinist
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/21/201509:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations